Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2023-05-15 AGM Information
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Chairman's Address to Shareholders 4 pages 154.9KB
AGM Information Classification · 95% confidence The document is a detailed text of the Chairman's address and Managing Director's business update delivered at the Annual General Meeting (AGM) of Cyclopharm Limited. It includes a formal welcome, agenda, financial performance highlights for the year 2022, strategic initiatives, board appointments, and operational updates. The text explicitly mentions it is part of the AGM proceedings and is addressed to shareholders. There is no indication that this is a full Annual Report (10-K) or an Earnings Release (ER). It is not a proxy statement or voting results announcement. The document is a presentation and speech material shared during the AGM, fitting the definition of AGM Information (AGM-R). The length and content confirm it is not a brief announcement or a certification, so it is not RNS or RPA. Therefore, the classification is AGM Information (AGM-R) with high confidence.
2023-05-15 English
CYC 2023 AGM Presentation 31 pages 2.4MB
AGM Information Classification · 95% confidence The document is titled '2023 Annual General Meeting' and contains content typical of an AGM presentation, including a Chairman's address, Managing Director's address, business updates, market opportunities, and strategic outlook. It includes forward-looking statements, operational highlights, and commercial plans, which are common in AGM materials. There is no indication that this is a full annual report (10-K) or an earnings release (ER). The document is lengthy (15,000 characters) and appears to be the presentation material used during the AGM rather than a simple announcement or regulatory filing. Therefore, the most appropriate classification is AGM Information (AGM-R).
2023-05-15 English
Managing Director's Address to Shareholders 8 pages 264.9KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Cyclopharm Ltd dated 16 May 2023, containing extensive financial performance data for the year 2022, operational highlights, growth objectives, regulatory updates, and market strategy including USFDA approval progress. It includes slides with financial highlights, sales data, and strategic outlook. The content is typical of an investor presentation focusing on financials, strategy, and market position rather than a formal annual report or regulatory filing. The length (15,000 characters) and detailed narrative with slides further support this classification. There is no indication that this is a full Annual Report (10-K), Audit Report, or Earnings Release. It is not a brief announcement or voting result. Therefore, the document best fits the category of an Investor Presentation (IP).
2023-05-15 English
Results of Meeting 2 pages 140.1KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement dated 16 May 2023 from Cyclopharm Limited regarding the results of their Annual General Meeting (AGM). It includes detailed voting results for each resolution passed at the AGM, referencing compliance with Listing Rule 3.13.2 and section 251AA of the Corporations Act. The content focuses on the voting outcomes rather than the full AGM materials or presentations. The document length is 3670 characters, which is relatively short and consistent with a voting results announcement rather than a full AGM report or presentation. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-05-15 English
Notification of buy-back - CYC 5 pages 24.6KB
Transaction in Own Shares Classification · 95% confidence The document is titled 'Notification of buy-back' and contains detailed information about an on-market buy-back of shares by Cyclopharm Limited. It includes specifics such as the type of buy-back, number of securities, broker information, and key dates. The content is focused on the company's share repurchase activity rather than financial results, management changes, or regulatory filings. The document length is 2873 characters, which is relatively short but contains substantive details about the buy-back itself, not just an announcement of a report. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers share repurchase activities.
2023-05-15 English
Cyclopharm Confirms USFDA Scheduled Inspection Date 2 pages 185.2KB
Regulatory Filings Classification · 95% confidence The document is an announcement from Cyclopharm Limited regarding the scheduling of a USFDA inspection for their Kingsgrove facility and updates on their New Drug Application review period. It discusses regulatory inspection dates, market expectations, and product information but does not contain financial statements, detailed financial performance data, or comprehensive management analysis. The document is relatively short (3343 characters) and serves as a regulatory update rather than a full report or detailed financial disclosure. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a certification or officer attestation. The content aligns best with a Regulatory Filing (RNS) as it is a general regulatory announcement about the FDA inspection and drug application status without detailed financial or operational data.
2023-05-08 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.